CPRXCatalyst Pharmaceuticals, Inc.

CPRX Stock Price, Valuation & Chart | Catalyst Pharmaceuticals, Inc.

Compare

$31.490+0.00 (+0.00%)

At close · 15 July 2026, 01:30 pm

Sector: Healthcare Industry: Biotechnology CPRX intrinsic value CPRX calculated fair value vs price

Overview Financials Dividends Ratios

CPRX Historical price chart

CPRX Key Stats

Fair Value

Disclaimer

Disclaimer: This fair value estimate is for informational purposes only and should not be considered as investment advice. Fair value calculations are based on DCF (Discounted Cash Flow), P/E Multiple, and P/S Multiple models and assumptions that may not reflect actual market conditions. Always conduct your own research and consult with a financial advisor before making investment decisions.

Unlock

Market Capitalization3.85B

PE Ratio12.3

EPS2.56

Trading Volume0

Today's High/Low31.49/31.49

Dividend Yield0.00

52 Week High/Low32.56/19.05

Shares Outstanding122.42M

CPRX Financial Statement

CPRX Analyst ratings

CPRX Analysis & performance metrics

CPRX Company profile

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic…

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the…

CPRX Management team

Name

Position

Preethi Sundaram Ph.D.

Chief Strategy Officer

Stanley Iyadurai M.D., Ph.D.

Senior Vice President of Medical Affairs & Drug Discovery

Gregg Russo

Chief Human Resources Officer

Steven R. Miller Ph.D.COO

Executive Vice President, Chief Operating Officer & Chief Scientific Officer

Jeffrey Del Carmen

Executive Vice President & Chief Commercial Officer

Michael W. Kalb CPACFO

Executive Vice President, Treasurer & Chief Financial Officer

Brian Elsbernd J.D.

Chief Compliance Officer & Chief Legal Officer

Gary Ingenito M.D., Ph.D.

Chief Medical & Regulatory Officer

Name

Position

Preethi Sundaram Ph.D.

Chief Strategy Officer

Stanley Iyadurai M.D., Ph.D.

Senior Vice President of Medical Affairs & Drug Discovery

Gregg Russo

Chief Human Resources Officer

Steven R. Miller Ph.D.COO

Executive Vice President, Chief Operating Officer & Chief Scientific Officer

Jeffrey Del Carmen

Executive Vice President & Chief Commercial Officer

Michael W. Kalb CPACFO

Executive Vice President, Treasurer & Chief Financial Officer

Brian Elsbernd J.D.

Chief Compliance Officer & Chief Legal Officer

Gary Ingenito M.D., Ph.D.

Chief Medical & Regulatory Officer

Management Team

Preethi Sundaram Ph.D.

Chief Strategy Officer

Stanley Iyadurai M.D., Ph.D.

Senior Vice President of Medical Affairs & Drug Discovery

Gregg Russo

Chief Human Resources Officer

Steven R. Miller Ph.D.COO

Executive Vice President, Chief Operating Officer & Chief Scientific Officer

Jeffrey Del Carmen

Executive Vice President & Chief Commercial Officer

Michael W. Kalb CPACFO

Executive Vice President, Treasurer & Chief Financial Officer

Brian Elsbernd J.D.

Chief Compliance Officer & Chief Legal Officer

Gary Ingenito M.D., Ph.D.

Chief Medical & Regulatory Officer

Management

Preethi Sundaram Ph.D.

Chief Strategy Officer

Stanley Iyadurai M.D., Ph.D.

Senior Vice President of Medical Affairs & Drug Discovery

Gregg Russo

Chief Human Resources Officer

Steven R. Miller Ph.D.COO

Executive Vice President, Chief Operating Officer & Chief Scientific Officer

Jeffrey Del Carmen

Executive Vice President & Chief Commercial Officer

Michael W. Kalb CPACFO

Executive Vice President, Treasurer & Chief Financial Officer

Brian Elsbernd J.D.

Chief Compliance Officer & Chief Legal Officer

Gary Ingenito M.D., Ph.D.

Chief Medical & Regulatory Officer

Total 8 executives

CPRX Frequently asked questions

What is Catalyst Pharmaceuticals, Inc. (CPRX) Stock Price?

Current stock price of Catalyst Pharmaceuticals, Inc. (CPRX) stock is $31.490. The stock price is +0.00% higher in the session. The intraday range can be seen from this page. Volume of Catalyst Pharmaceuticals, Inc. (CPRX) stock is 0.

Last updated at 15 July 2026, 01:30 pm.

Why is the Catalyst Pharmaceuticals, Inc. (CPRX) stock price going up or down today?

The stock price of Catalyst Pharmaceuticals, Inc. (CPRX) can change with earnings, company news, and overall market sentiment. Catalyst Pharmaceuticals, Inc. operates in the Healthcare / Biotechnology market, so sector-wide moves can also affect the share price. Use the live price, percentage change, and volume on this page to judge whether a move looks meaningful.

Is the Catalyst Pharmaceuticals, Inc. stock expensive at its current price?

Whether Catalyst Pharmaceuticals, Inc. looks expensive depends on valuation metrics versus its growth outlook. The P/E ratio shown for CPRX on this page is 12.30. EPS on this page is 2.56. Compare those figures with peers and growth expectations before deciding if the current Catalyst Pharmaceuticals, Inc. price is justified.

How has the stock price of Catalyst Pharmaceuticals, Inc. (CPRX) performed historically?

Historical performance for Catalyst Pharmaceuticals, Inc. (CPRX) is shown on the price chart on this page. Review multi-period moves alongside volume to see how CPRX reacted to past earnings and market events.

Should I buy Catalyst Pharmaceuticals, Inc. (CPRX) stock, at this price?

Buying Catalyst Pharmaceuticals, Inc. (CPRX) depends on your risk tolerance, time horizon, and portfolio needs. As a Healthcare name, weigh the live quote, key stats, and valuation links on this page rather than a single price point.